Read research from the March 2023 session of the ASCO Plenary Series, which highlights a study evaluating a new targeted therapy drug given in combination with chemotherapy for people with advanced gastric or gastroesophageal junction cancer.
Drs. David Ilson, Sumanta (Monty) Pal, and Tian Zhang discuss new research presented at the 2022 ESMO Congress, including studies about treating liver, colorectal, stomach, kidney, bladder, and prostate cancers.
ASCO’s 2021 Advance of the Year highlights how progress in the treatment of gastrointestinal (GI) cancers is driven by molecular testing of tumors.
Cancer.Net Associate Editors explain research presented at the 2019 ASCO Annual Meeting, including new research in colon cancer, gastric cancer, pancreatic cancer, and leukemia.
The ASCO Annual Meeting is where many new cancer research findings are announced. Today’s key research highlights include treatment advances for advanced lung cancer, stomach cancer, gastroesophageal junction cancer, and breast cancer.
When cancer treatment ends, where does post-treatment survivorship care begin? For caregiver Aki Smith and her dad, a stomach cancer survivor, the answer was in the office of a primary care physician.
When Randy Hillard was diagnosed with metastatic stomach cancer in 2010 he was treated with a drug that increased overall survival to an average of 13 months. Now, nearly 5 years later, his unexpected survival has led to some unexpected issues.
Connecting with others who know exactly what you are going through provides much-needed support for many people with cancer. Randy Hillard, MD, talks about how joining (and now administrating) an online group for people with stomach cancer offers so much more than support.
